Psychedelic Business Spotlight – April 15
This week in psychedelic business news: The industry’s first major merger; NeonMind launches clinics; a portfolio of patents is acquired.
NeonMind
Psilocybin Is Effective in Reducing Weight Gain, New Study Shows
NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects.
Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic
The psychedelic bioscience company’s top advisor tells Psychedelic Spotlight that psilocybin “affects at least the 5h2C receptor, which is dedicated towards appetite and appetite suppression.”
Interview with Trevor Millar, Advisor, NeonMind Biosciences
In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle obesity. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese.
Psychedelic Business Spotlight: September 17, 2021
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
End of content
End of content